Pharma Journalist -

Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors. The study findings could help…
Read More...

VBI Vaccines announced positive final top-line results from the randomized, placebo-controlled Phase 1 study of VBI-1501, the company’s prophylactic cytomegalovirus (CMV) vaccine…
Read More...

Lodo Therapeutics Corporation, a drug discovery and development company focused on identifying and producing unique, bioactive natural products directly from the microbial DNA sequence…
Read More...

Eli Lilly and Company and ARMO BioSciences, Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction.…
Read More...

AcelRx Pharmaceuticals announced the resubmission of the New Drug Application (NDA) for DSUVIA with the U.S. Food and Drug Administration (FDA). AcelRx anticipates that the FDA will…
Read More...

miRagen Therapeutics announced new interim data from its Phase 1 clinical trial of cobomarsen in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). The…
Read More...

SMi Reports: Two new speakers and sponsor have been announced to be joining the 8th annual BioBanking conference, taking place this June in London, UK There is just over a month…
Read More...

XtalPi Inc. announced a strategic research collaboration with Pfizer Inc. to develop a hybrid physics- and artificial intelligence (AI)-powered software platform for accurate molecular…
Read More...

Takeda Pharmaceutical Company Limited and Shire plc announced that they have reached agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire…
Read More...

In patients who have suffered from a heart attack, a large portion of heart cells die, which may cause heart failure and significant mortality and morbidity. The aim of the…
Read More...